PRRT2 and hepatocellular carcinoma: BisI, which blocked the PKC activities, significantly increased the viral copy of DENV2 strain 16681 in human hepatocellular carcinoma HepG2 cells, with the highest copy number of the virus attained by the 0.1 and 1 μM BisI treatments (Fig. 4a).